Kane Biotech (TSE:KNE) has released an update.
Kane Biotech, a company specializing in biofilm research, has expanded its global reach with a new three-year distribution agreement for its revyve™ Antimicrobial Wound Gel in Qatar. This marks Kane Biotech’s second distribution deal in the Middle East, reflecting the company’s continuous effort to commercialize their product internationally. The agreement is expected to strengthen Kane Biotech’s presence in the global wound care market.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
